
Orkambi Study On Children Age 6-12 With DDF508: Cystic Fibrosis Treatment
Results are in from a 24-week study of Orkambi (lumacaftor/ivacaftor – a medication used in cystic fibrosis treatment) in 58 children with cystic fibrosis age 6-12 with two copies of the F508-delta mutation. Researchers were looking to examine the safety and efficacy of the CFTR potentiator on this age group and …

Thank YOU! This research is complete!
All of the goals were met in 20 hours! This community loves to be part of research. Thank you! Research Opportunities! $40.00 Gift Card to Complete On-Line Research This research opportunity involved 5-17 year old on Pulmozyme. It was for both patients and caregivers.

SuperHero DNA
Study finds individuals immune to severe diseases. A new study has found that certain people’s genes have evolved in such a way that they are immune to certain severe inherited conditions. The study involved the analysis of previously collected DNA sets totaling 589,306 genomes from around the world with researchers hoping …